Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of CKD-348 vs Co-administration of CKD-828, D326, and D337 in Healthy Volunteers
NCT04272502Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Jun 2019
- Primary completion
- Aug 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of telmisartan, Levamlodipine, rosuvastatin and ezetimibe in hypertension (HTN) and dyslipidemia (3 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Maximum Plasma Concentration and Area Under the Concentration-Time Curve to the Last Measurable Concentration. Started Jun 2019; status: completed.
02
Drugs
telmisartanLevamlodipinerosuvastatinezetimibe
03
Conditions
hypertension (HTN)dyslipidemia
Beyond the preview
Go deeper on NCT04272502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04272502.